Gentium S.p.A. Receives Positive Opinion From European Medicines Agency's COMP for Defibrotide for the Prevention of GvHD
Published: Oct 11, 2013
VILLA GUARDIA, Italy, Oct. 10, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Medicines Agency's Committee for Orphan Medicinal Products ("COMP") has issued a positive opinion on the Company's application for orphan medicinal product status for Defibrotide for the prevention of Graft versus Host Disease ("GvHD"). The positive opinion of the COMP has now been forwarded to the EU commission for final approval and publication in the EU community register.
Help employers find you! Check out all the jobs and post your resume.